Quantcast

Latest Natalizumab Stories

2008-07-23 12:01:11

Biogen Idec has reported total revenue of $993 million for the second quarter of 2008, an increase of 28% compared to total revenue of $773 million for the same quarter of 2007. The company posted a net income of $207 million in the second quarter of 2008, an increase of 11% compared to $186 million in the second quarter of 2007. Second quarter 2008 diluted earnings per share (EPS) was $0.70, an increase of 30% from $0.54 reported in the second quarter of 2007. James Mullen, Biogen...

2008-07-23 03:00:22

By Blasier, Mary Gail Key Words: Multiple sclerosis, central nervous system, disease modifying therapies, quality of life. Multiple sclerosis (MS) is a chronic disease of the central nervous system (CNS), which is composed of the brain, optic nerves, and spinal cord (Graham, 2009). It is thought to be an autoimmune disorder that afflicts approximately 400,000 Americans in early to middle adulthood (ages 20 to 40) (National Multiple Sclerosis Society [NMSS], 2008). About 200 people are newly...

2008-07-22 03:00:18

Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) today announced the two-year anniversary of TYSABRI(R) (natalizumab) as a treatment for relapsing forms of multiple sclerosis (MS), marking the reintroduction of the product in the United States (US) and the first international approval. The companies estimate that as of the end of June 2008, more than 31,800 patients worldwide are receiving TYSABRI treatment. Specifically, as of the end of June 2008: -- In the US,...

2008-03-05 12:01:03

ROCHESTER, N.Y., March 5 /PRNewswire/ -- Vaccinex, Inc. announced today that Dr. John E. Leonard has joined its Scientific Advisory Board, and will be actively involved in the strategic planning and execution of the company's therapeutic antibody development programs. Dr. Leonard has over 20 years of experience at Idec and Biogen Idec, having held Senior Director level positions in Regulatory Affairs, Quality, Project Management and Product Development, and Vice President level positions...

41057fcb119e40c307ac9d112e9ad5371
2008-01-15 08:59:38

The Food and Drug Administration (FDA) announced Monday it had approved Tysabri, a drug used to treat multiple sclerosis, for use in patients with moderate to severe Crohn's disease.However, the approval comes with a warning that the drug has the risk of causing a rare but serious brain infection.  Crohn's disease is a painful, serious, inflammatory bowel disease that afflicts over half a million people in the United States.   There is no known cure, and the disease typically...

2007-02-19 12:00:11

By Diedtra Henderson, The Boston Globe Feb. 19--WASHINGTON -- For patients suffering from a severe form of Crohn's disease, a remedy already on the shelf to treat other maladies and a brand-new drug could offer new hope. Within days, Illinois-based Abbott Laboratories expects to win federal approval to sell its drug, Humira, currently used to treat rheumatoid arthritis, psoriatic arthritis, and a disease that causes arthritis of the spine, to combat the intestinal disorder. The...

2006-06-05 16:35:00

By Susan Heavey WASHINGTON (Reuters) - U.S. health officials cleared the way on Monday for multiple sclerosis drug Tysabri to return to the market with restrictions, following its withdrawal last year when it was linked to a rare but potentially fatal brain disease. Three patients taking the drug, made by Biogen Idec Inc. and distributed by Elan Corp., had developed progressive multifocal leukoencephalopathy (PML). Two of them died. Food and Drug Administration officials, who faced calls from...

2006-06-05 13:03:11

WASHINGTON (Reuters) - Biogen Idec Inc. and Elan Corp. won permission on Monday to resume sales of their multiple sclerosis drug Tysabri, which was withdrawn last year after it was linked to a rare but potentially fatal brain disease, U.S. regulators said. The U.S. Food and Drug Administration said Tysabri must be sold under a restricted distribution plan to minimize chances of harm. Tysabri should be used as a stand-alone treatment and not with other drugs that suppress the immune...

2006-04-07 03:51:55

By Michael Smith DUBLIN (Reuters) - Elan Corp. Plc said on Friday the latest trials of its multiple sclerosis drug Tysabri showed significant positive results in patients, sending its shares higher. "The Tysabri study data show not only significant reductions in relapses and disability, but also suggest improved quality of life. This is very encouraging," the company said in a statement. Elan and drugmaker Biogen Idec faced a fresh delay in getting Tysabri back to the market last...

2006-04-07 01:44:27

DUBLIN (Reuters) - Elan Corporation Plc said on Friday the latest trials of its multiple sclerosis drug Tysabri on sufferers showed significant positive effects on their quality of life. "The Tysabri study data show not only significant reductions in relapses and disability, but also suggest improved quality of life. This is very encouraging," the company said in a statement. Elan and drugmaker Biogen Idec faced a fresh delay in getting Tysabri back to the market last month after...


Word of the Day
bellycheer
  • Good cheer; viands.
  • To revel; to feast.
The word 'bellycheer' may come from 'belle cheer', "good cheer".
Related